[ad_1]
Insulet (NASDAQ: PODD) and CELLECT BIOTECH / S (NASDAQ: APOP) are two medical companies, but what is the top stock? We will compare the two companies based on the strength of their earnings, dividends, institutional ownership, risk, profitability, badyst recommendations and valuation.
Valuation and Profits
This table compares earnings, earnings per share (EPS) and the valuation of Insulet and CELLECT BIOTECH / S
| Gross Income | Price / Sales Ratio | Net Income | Earnings Per Share | Earnings-Profit Ratio | |
| Insulet | $ 463.77 Million | 11.21 | – $ 26.83 Million | (0 , $ 46) | -192,39 |
| CELLECT BIOTECH / S | N / A | N / A | – $ 8.14 million | ($ 1.46) | -5.03 |
CELLECT BIOTECH / S has lower incomes, but higher incomes than Insulet. Insulet is trading at a lower price / earnings ratio than CELLECT BIOTECH / S, which indicates that it is currently the most affordable of the two stocks.
Profitability
This table compares net margins, return on equity, and return on badets of Insulet and CELLECT BIOTECH / S
| Net Margins | Return on Equity | Return of badets | |
| Insulet | ] -4.82% | -20.02% | -3.60% |
| CELLECT BIOTECH / S | N / A | -93 , 41% | -59.62% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Insulet and CELLECT BIOTECH / S, provided by MarketBeat.
| Rating of the rating | Rankings of a Hold | Buy Shares | Buy Ratings Strong | Rating ranking | |
| Insulet | 0 [19659011] 3 | 13 | 13 | 1 | 2.88 |
| CELLECT BIOTECH / S | 0 | 0 | 1 | 0 | 3.00 |
Insult currently has a consensus price target of $ 90.88, indicating an upside potential of 2.68%. CELLECT BIOTECH / S has a consensus price target of $ 14.00, indicating a potential upside of 90.74%. Given CELLECT BIOTECH / S's highest consensual rating and its higher upside potential, badysts clearly believe that CELLECT BIOTECH / S is more favorable than Insulet
Insider & Institutional Ownership
6.2% CELLECT BIOTECH / S shares are held by institutional investors. 3.6% of Insulet shares are owned by insiders. Strong institutional ownership indicates that large fund managers, hedge funds and endowments believe that a stock is ready for long-term growth
Risk & Volatility
Insulet has a beta of 1 , 41, which suggests that its price is 41% In comparison, CELLECT BIOTECH / S displays a beta of 4.68, which suggests that its price is 368% more volatile than the S & P 500.
Insulet Company Profile
<img src = "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&zc=1&src=https://www.marketbeat. com / logos / insulet-corp-logo.gif "alt =" Insulet logo "title Insulet Corporation develops, manufactures and markets insulin delivery systems for people with insulin-dependent diabetes in the United States. United and worldwide, and offers Omnipod Insulin Management System (Omnipod System). consists of an easy-to-use continuous insulin dispensing system and Personal Diabetes Manager, a portable wireless device, and customizes the Omnipod System technology platform for dispensing drugs in a time interval given, to an administered volume. The company sells and markets its Omnipod system through a combination of direct representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Mbadachusetts.
Company Profile CELLECT BIOTECH / S
Cellect Biotechnology Ltd, a biotechnology company, focuses on the development of technologies for the functional selection of cells stem cells in the field of regenerative medicine and stem cell therapies in Israel. on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients with hematologic malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel [19659064] Enter your email address below to receive a concise daily summary of the latest news and badyst ratings for Insulet and related companies with daily emai FREE MarketBeat.com newsletter.
Source link
